Based on these controversial conclusions, the clinical usefulness of Her2/neu ECD is still largely unknown in breast cancer and further studies are needed to clarify the real clinical implications of Her2/neu ECD shedding in the context of trastuzumab-based therapy. Here, ERBB2 is linked to breast carcinoma.